AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22321321
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pioglitazone hydrochloride once daily for 16 weeks
Trial: 14745704
Drug: PIV3-cp45 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIV3-cp45 vaccine
Trial: 31527299
Drug: Non-randomized surgical
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-randomized surgical treatment
Trial: 23692328
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of 150-200 ml milk
Trial: 23692328
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly intake of 150-200 ml milk
Trial: 23692328
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (daily and twice weekly)
Trial: 21502577
Drug: Atopaxar (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopaxar (400 mg loading dose followed by 50, 100, or 200 mg daily)
Trial: 8715845
Drug: Rectal temperatures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal temperatures
Trial: 1398956
Drug: Single 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 x 10(8)‐CFU dose of live oral recombinant cholera vaccine CVD 103‐HgR
Trial: 3987797
Drug: Trimebutine 100
RxNorm normalized name: trimebutine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine 100 mg i.v.
Trial: 3358881
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg three times daily
Trial: 28417910
Drug: L-CHO
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-CHO
Trial: 14749569
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous platelet‐enriched plasma combined with bovine collagen and thrombin (PCT)
Trial: 14749569
Drug: Gelfoam/thrombin (G/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelfoam/thrombin (G/T)
Trial: 11148527
Drug: pH‐dependent, enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH‐dependent, enteric‐coated peppermint oil capsules
Trial: 9631143
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human insulin-like growth factor type 1 (rhIGF-1)
Trial: 9631143
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of rhGH and rhIGF-1
Trial: 9631143
Drug: All therapies
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All therapies (rhGH, rhIGF-1, combination)
Trial: 7829435
Drug: Dose schedule
RxNorm normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose schedule No.1 (group 2)
Trial: 7829435
Drug: Dose schedule
RxNorm normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose schedule No.2 (group 3)
Trial: 30816056
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg/day
Trial: 20947174
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER (3-12 mg/day) as adjunctive therapy
Trial: 20947174
Drug: Mood stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood stabilizer monotherapy (valproate or lithium)
Trial: 19277690
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg methyl‐ergometrine intramuscularly
Trial: 15472840
Drug: Live, attenuated,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, attenuated, cold-adapted influenza vaccine (CAIV-T)
Trial: 11682400
Drug: tandospirone 10
RxNorm normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tandospirone 10 mg (T10 group)
Trial: 11682400
Drug: tandospirone 30
RxNorm normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tandospirone 30 mg (T30 group)
Trial: 11682400
Drug: diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 10 mg (D group)
Trial: 3680600
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg nortriptyline test dose
Trial: 3680600
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg nortriptyline
Trial: 3680600
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nortriptyline
Trial: 28085707
Drug: Citicoline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (100 mg twice a day)
Trial: 21371281
Drug: Preventive ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive ceftriaxone treatment (2 g, given every 24 h intravenously for four days)
Trial: 21371281
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care without preventive antibiotic treatment
Trial: 21371281
Drug: Preventive ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive ceftriaxone treatment
Trial: 17202203
Drug: Sealed capsule
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealed capsule irrigation (SCI) using distilled water for 2 minutes after phacoemulsification
Trial: 15189176
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin alfa administration (group A)
Trial: 15189176
Drug: Intravenous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoetin alfa administration (group B)
Trial: 15189176
Drug: Intravenous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoetin alfa administration (group A after switch)
Trial: 15189176
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin alfa administration (group B after switch)
Trial: 8988824
Drug: Mivacurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.15 mg.kg-1 followed by 0.1 mg.kg-1
Trial: 8988824
Drug: Rocuronium 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.9 mg.kg-1 followed by placebo
Trial: 8988824
Drug: Divided dose
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided dose mivacurium
Trial: 3508426
Drug: DMSO (hydroxyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSO (hydroxyl radical scavenger), administered locally 5 times a day for one week
Trial: 3508426
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered for one week
Trial: 24887747
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol propionate 0.05% applied three times a day
Trial: 22383268
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive group therapy
Trial: 10599260
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg once or twice a day)
Trial: 10599260
Drug: Amoxicillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (3 g/d), Amoxicillin/clavulanic acid (1500 mg/d), Ceftriaxone (1-4 g/d)
Trial: 7499116
Drug: Investigational direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational direct compression tablet
Trial: 1449568
Drug: Corticosteroids in
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids in combination with albuterol
Trial: 1449568
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with different corticosteroids in combination with albuterol
Trial: 30289802
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nutrition supplementation and education
Trial: 20660677
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg intravenous infusion of PRO 140
Trial: 20660677
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg intravenous infusion of PRO 140
Trial: 17986493
Drug: Cardiac-resynchronization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac-resynchronization therapy (CRT)
Trial: 16321612
Drug: Nicotine vaccine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine vaccine (200 microg)
Trial: 16321612
Drug: Nicotine vaccine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine vaccine (50 microg)
Trial: 16321612
Drug: Nicotine vaccine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine vaccine (100 microg)
Trial: 16321612
Drug: Nicotine vaccine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine vaccine (50, 100, 200 microg)
Trial: 8065789
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion system with 0.125% plain bupivacaine
Trial: 2903604
Drug: Lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1 mg kg‐1
Trial: 31645442
Drug: NZ8123-HPV16-optiE7 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZ8123-HPV16-optiE7 vaccine (5 × 109 CFU/mL)
Trial: 31645442
Drug: NZ8123-HPV16-optiE7 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZ8123-HPV16-optiE7 vaccine (1 × 1010 CFU/mL)
Trial: 31645442
Drug: NZ8123-HPV16-optiE7 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZ8123-HPV16-optiE7 vaccine (1 × 109 CFU/mL)
Trial: 11072157
Drug: Preoperative chemo-radiation
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative chemo-radiation (4760 cGy to primary and lymph nodes with concurrent chemotherapy: cisplatin/5-FU)
Trial: 1547683
Drug: Pork insulin
RxNorm normalized name: Pork insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork insulin
Trial: 3884408
Drug: Lormetazepam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (oral drops)
Trial: 23912798
Drug: MTX +
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX + intravenous steroid
Trial: 22982023
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) treatment for 30 months
Trial: 22982023
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after stopping ICS treatment for 24 months
Trial: 20381890
Drug: Self-administered intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intervention to assist patients in formulating plans for self-monitoring of blood glucose (SMBG)
Trial: 11889577
Drug: Antioxidant cocktail
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant cocktail (vitamin E 500 mg/day, beta-carotene 30 mg/day, vitamin C 1 g/day for last 15 days)
Trial: 8824473
Drug: Microemulsion formulation
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microemulsion formulation of cyclosporine
Trial: 10071350
Drug: Original formulation
RxNorm normalized name: Zegerid (Original Formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original formulation of cyclosporine
Trial: 7675951
Drug: Caffeine 75
RxNorm normalized name: caffeine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 75 mg
Trial: 2286708
Drug: Fluphenazine (10-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine (10-30 mg/day)
Trial: 7434788
Drug: Sulindac 200-400
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 200-400 mg/day for 4 weeks
Trial: 7434788
Drug: Sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 200 mg in 10 healthy volunteers
Trial: 27718637
Drug: New L-T4
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: New L-T4 formulation (600 μg)
Trial: 27718637
Drug: Current L-T4
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Current L-T4 formulation (600 μg)
Trial: 27718637
Drug: L-T4 tablets
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-T4 tablets (50 μg, 100 μg, 200 μg)
Trial: 21860291
Drug: Prescription for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription for refills
Trial: 15549369
Drug: Hot treatment
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot treatment (immersion in hot water at 43 degrees C for 16.0 min)
Trial: 15549369
Drug: Hot treatment
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot treatment
Trial: 11572325
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) and oxandrolone therapy
Trial: 9260058
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with autotransplantation
Trial: 9260058
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy (bisphosphonates and erythropoietin)
Trial: 3663884
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of quinidine gluconate and procainamide hydrochloride
Trial: 3663884
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose administration of quinidine gluconate and procainamide hydrochloride
Trial: 28540562
Drug: Home-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based oral fluid rapid HIV self-testing
Trial: 25070393
Drug: Control (blister
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (blister pack solution)
Trial: 23127342
Drug: Inhaled Salmeterol/fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Salmeterol/fluticasone (SF) delivered by a metered-dose inhaler with a spacer
Trial: 23127342
Drug: Inhaled nebulized
RxNorm normalized name: Hydra-Neb Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nebulized ipratropium/terbutaline/budesonide (ITB)
Trial: 23127342
Drug: Inhaled Salmeterol/fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Salmeterol/fluticasone (SF)
Trial: 18515448
Drug: 3-day taper
RxNorm normalized name: Zema-Pak 13-Day TaperPak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day taper
Trial: 18515448
Drug: 14-day taper
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day taper
Trial: 18515448
Drug: short half-life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short half-life antidepressants
Trial: 15733932
Drug: L-5-hydroxytryptophan (5-HTP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan (5-HTP; 4 mg/kg in non enteric-coated tablets)
Trial: 10349695
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alfa-2b (rIFN-alpha 2b) plus oral ribavirin (1,000 or 1,200 mg)
Trial: 10349695
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alfa-2b (rIFN-alpha 2b) monotherapy
Trial: 10349695
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (rIFN-alpha 2b alone and combination therapy)
Trial: 1772105
Drug: RU41740 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU41740 (2 mg daily for one week in the first month, 1 mg daily for one week in the second month)
Trial: 7075104
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg Digoxin + Placebo (PL2)
Trial: 7075104
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg Digoxin + Quinidine (Q)
Trial: 7075104
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg Digoxin
Trial: 7075104
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg Digoxin + Sparteine (SP)
Trial: 24863486
Drug: PsA-TT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PsA-TT vaccine (Meningococcal group A polysaccharide conjugated to tetanus toxoid)
Trial: 24863486
Drug: Mencevax ACWY
RxNorm normalized name: meningococcal ACWY, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mencevax ACWY (quadrivalent plain polysaccharide vaccine)
Trial: 22277697
Drug: 18% benzocaine/2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18% benzocaine/2% tetracaine gel
Trial: 17329509
Drug: 0.87 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.87 g/d E2 gel
Trial: 17329509
Drug: 1.7 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 g/d E2 gel
Trial: 17329509
Drug: 2.6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6 g/d E2 gel
Trial: 15215483
Drug: Folate therapy
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate therapy (1 mg of folic acid, 5 mg of vitamin B6, and 1 mg of vitamin B12 intravenously, followed by daily oral doses of 1.2 mg of folic acid, 48 mg of vitamin B6, and 60 microg of vitamin B12 for six months)
Trial: 9509065
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg orally for 4 days at 1700 hours
Trial: 3177433
Drug: r‐HuEPO 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO 150 unit/kg intravenously three times weekly
Trial: 3177433
Drug: r‐HuEPO 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO 50 unit/kg intravenously three times weekly
Trial: 3177433
Drug: r‐HuEPO 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO 100 unit/kg intravenously three times weekly
Trial: 3177433
Drug: r‐HuEPO (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO (all doses)
Trial: 28329863
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (n = 228)
Trial: 24388167
Drug: Dinaciclib (IV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib (IV, 50 mg/m2)
Trial: 24388167
Drug: Erlotinib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (oral, 150 mg)
Trial: 22486141
Drug: Sildenafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (20 mg tablets twice a day for one week)
Trial: 22486141
Drug: Placebo (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablets with the same dosage as sildenafil)
Trial: 8917247
Drug: Clarithromycin, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, 10 mg/kg per day, twice a day for 7 days
Trial: 8917247
Drug: Azithromycin, 10
RxNorm normalized name: Azithromycin, 100 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 10 mg/kg per day, once a day for 5 days
Trial: 1899732
Drug: High-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroid treatment (0.5 g solumedrol) before or at the same time as the first OKT3 injection
Trial: 1899732
Drug: High-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroid treatment (0.5 g solumedrol) before the first OKT3 injection
Trial: 7040581
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg oral dose
Trial: 26716866
Drug: Dexmedetomidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.0 μg kg(‐1) loading dose over 10 min followed by 0.5 μg kg(‐1) h(‐1) during one-lung ventilation)